In the United States, the legislative proposal to limit prescription drug spending has entered the core stage, and its purpose is that Congress passes this law to pay for the cost of repairing national infrastructure, offsetting global warming, and expanding health care programs

The CBO report explains that if Congress approves legislation that allows medical insurance to limit the reimbursement of certain major drugs, why companies investing in new drug development may abandon long-term and expensive drug research

Reduce investor interest in the biotechnology market

Pharmaceutical companies are also very concerned about the potential harm of these proposed pricing policies to the prescription drug market

 Another response to concerns about the decline in new drug R&D is that any decline in industry R&D can be offset by increasing government support to the National Institutes of Health -perhaps part of the savings from the proposed legislation can be used for this purpose

Original Title: Will Price Controls Limit Drug Development? The Debate Heats Up

Author: Jill Wechsler, Pharm Exec's Washington Correspondent

Original link: https://